Barclays Lowers its Price Target on Hims & Hers Health, Inc. (HIMS) to $25 and Keeps an Overweight Rating

Hims & Hers Health, Inc. (NYSE:HIMS) is among the 10 Fastest Growing NYSE Stocks to Buy. Barclays Lowers its Price Target on Hims & Hers Health, Inc. (HIMS) to $25 and Keeps an Overweight Rating On February 24, 2026, Barclays lowered its price target on Hims & Hers Health, Inc. (NYSE:HIMS) to $25 from $48 and kept an Overweight rating on the shares. That same day, TD Cowen analyst Jonna Kim lowered the firm’s price target to $17 from $20 and maintained a Hold rating, citing near-term pressure until there ...